Abstract
Introduction
Osteoporosis afflicts a large number of populations in the world and it is featured by systemic impairment of bone mass and strength which may further cause an increase in the risk of fragile fractures [1] . The prevalence of osteoporosis is predicted to rise steadily and this may result in substantial increase in financial costs as the number of patients with osteoporosis continues to increase. About $ 17 billion was spent on tackling osteoporotic fractures in the US every year and non-vertebral fractures accounted for 94% of total costs associated with this disease [2] . Furthermore, roughly 70% fracture cases are related to osteoporosis and these fractures usually occur in non-vertebral locations including hip, wrist and humerus [2, 3] . Postmenopausal females are more vulnerable to osteoporosis potentially due to the lower level of oestrogen [4] and it is estimated that 30% of all postmenopausal females in the US and Europe suffered from osteoporosis [5] . Hence, researchers are inspired by discovering effective therapies that can be used to prevent non-vertebral osteoporoticrelated fractures particularly for postmenopausal females.
Various pharmacological agents have been developed for osteoporotic fractures and antiresorptive therapies such as bisphosphonates (i.e. alendronate (ALE), risedronate (RIS), clodronate (COL)), human parathyroid hormone (PTH), selective estrogen (EST) receptor modulators (raloxifene (RAL)) are probably the most popular ones [6] . Bisphosphonates is the first-line therapy that is currently available for postmenopausal osteoporosis and they act their functions by inhibiting the status of bone turnover [7] . For instance, COL is a kind of oral bisphosphonates which exhibits significant anti-resorptive effect on a variety of diseases related to increased bone resorption [8] . Teriparatide (TER), an anabolic PTH analogue, has been approved for postmenopausal osteoporosis in the US and Europe, and patients treated by TER were associated with a remarkable reduction in the risk of non-vertebral fractures [9] . RAL is a selective EST receptor modulator which has also been approved for postmenopausal osteoporosis in females who are at an increased risk of fracture [10] . Moreover, denosumab (DEN) is an antiresorptive agent with a novel mechanism. For instance, DEN is a fully human monoclonal antibody that targets and binds with the receptor activator of nuclear factorkappa B (RANKL) [11] which plays a key role in bone loss observed in osteoporosis [12] . Since the number of therapies that are able to reduce the risk of osteoporotic fractures has been increasing, comparing the relative efficacy and safety of these therapies is an essential task that has been mentioned by clinicians.
Although the effectiveness of the therapies we mentioned above has been confirmed by evidence obtained from randomized controlled trials comparing one with placebo (PCB), the lack of evidence with respect to head-to-head comparisons is a major limitation in the current literature [13, 14] . Besides, some therapies were rarely compared with others due to ethical issues [15] . As a result of this, we decided to adopt the approach of network metaanalysis (NMA) to overcome these limitations and distinguish therapies those are more preferable than others with respect to efficacy and safety. In our NMA, a total of ten therapies were selected and compared: ALE, COL, DEN, etidronate (ETI), RAL, RIS, strontium ranelate (STR), TER, zoledronic acid (ZOL) and EST + progestin (PRO).
Material and Methods

Search Strategy
We began our research by searching medical databases including China National Knowledge Internet (CNKI), PubMed and Embase for relevant literatures, without any restrictions on language. The following terms as well as their corresponding synonyms were included into the searching strategy: "postmenopause", "bone fractures", "postmenopausal osteoporosis", "alendronate", "clodronate", "denosumab", "etidronate", "raloxifene", "risedronate", "strontium ranelate", "teriparatide", "zoledronic acid", "selective estrogen + progestin" and "randomized controlled trial". Reference lists of retrieved articles and other potential data sources were also reviewed manually to avoid omission. Then retrieved studies were screened by two reviewers independently. Any disagreement with respect to literature selection was solved by discussion and mediation.
Selection criteria
Studies to be included in our research must meet the following criteria: 1) Randomized controlled trials in which subjects were diagnosed with postmenopausal osteoporosis; 2) More than 30 subjects were included in the study; 3) At least one pairwise comparison between the above mentioned interventions (ALE, COL, DEN, ETI, RAL, RIS, STR, TER, ZOL, EST+PRO, PCB) was involved in the study; 4) Study should contain sufficient data for the purpose of NMA; 5) At least one of the following endpoints were assessed by the study: new non-vertebral fractures, hip fractures, wrist fractures, adverse events.
Data extraction
Once eligible studies were selected, two independent researchers would conduct data extraction to obtain relevant information contained in each eligible study. Name of author, publication year, study design, duration of follow-up, sample size, mean age, years since menopause and type of intervention were documented for analysis. This NMA was designed to compare the relative efficacy and safety of different interventions. New non-vertebral fractures were considered as the primary endpoint whereas secondary endpoints include hip fractures, wrist fractures and adverse events. Any discrepancy with respect to data extraction was settled after discussion based on expert knowledge.
Statistical analysis
Conventional pair-wise meta-analysis (MA) was carried out prior to the implementation of NMA. Then, a closed loop of network among the interventions was carried out in order to conduct the corresponding NMA. Both direct and indirect evidence were utilized to compare the efficacy of various treatments, which was described by odds ratios (OR) and 95% credible intervals (CrI) with a significance level at 0.05. The implementation of NMA was carried out according to the Bayesian framework by using the R 3.2.3 software. Moreover, ORs and their corresponding 95% CrIs obtained from the conventional MA and NMA were compared to assess the degree of consistency between direct and indirect evidence. Moreover, the surface under cumulative ranking curve (SUCRA) was adopted to rank probabilities with respect to each clinical outcome. A higher SUCRA value indicates a more desirable property with respect to a certain endpoint. Assessment of heterogeneity among eligible studies was carried out according to Cochran's Q-statistic and I 2 test. Significant heterogeneity was concluded if P-value of Cochran's Q-test was less than 0.01 or I 2 proved to be larger than 50%. Under such a circumstance, the random-effects model (DerSimonian-Laird method) was used to replace the fixed-effect model (Mantel-Haenszel method) in order to improve accuracy of research.
Results
Study Characteristics
Initially, 1,444 publications were identified through database searching from CNKI, PubMed, Embase and 1,372 studies were excluded by reviewing their titles and abstracts. Among 72 articles remained, we carried out full-text review and 35 articles from 1990 to 2014 were finally selected while the remaining articles were eliminated for their contradiction against the inclusion criteria mentioned above [13, . The entire process of literature search, identification and selection is illustrated in Fig. 1 . The network plot was depicted in order to visualize the corresponding evidence and comparisons among these interventions Fig. 2 . Interventions in our study were divided into the following groups based on the corresponding type of medication: PCB, ALE, COL, DEN, ETI, RAL, RIS, STR, TER, ZOL and EST+PRO. The clinical outcomes we studied were as follows: new non-vertebral fractures, hip fractures, wrist fractures and adverse events. Baseline characteristics and primary outcomes of included studies were summarized in Table 1 .
New non-vertebral fractures
Comparison among treatments with respect to new non-vertebral fractures was displayed in Table 2 
Hip fractures
Comparisons of interventions with respect to hip fractures were listed in Table 2 and comparison between STR and PLA, ALE, COL, DEN, RAL, RIS; RIS and TER, ZOL and EST+PRO were not included due to the lack of relevant data.
Wrist fractures
Comparisons of interventions with respect to the risk of wrist fractures were presented in Table 2 and Fig. 5 . As all the 95% credible intervals include 1, no significant difference in the risk of wrist fractures was observed among patients treated by different interventions. Besides, several comparisons among DEN, ZOL and other medications were not feasible due to the lack of evidence.
Adverse events
For patients diagnosed with postmenopausal osteoporosis, Table 2 and Fig. 6 illustrated the corresponding comparison among interventions with respect to the risk of adverse events. Our NMA revealed that patients treated by ZOL exhibited significantly increased risk of adverse events in comparison to those treated by PCB (OR = 1.44, 95% CrI: 1.08-1.99), ALE (OR = 1.58, 95% CrI: 1.10-2.27), DEN (OR = 1.50, 95% CrI: 1.04-2.27) and RAL (OR = 1.77, 95% CrI: 1.13-2.55). Therefore, patients treated by ZOL were likely to be under an increased risk of adverse events compared to other medications.
Assessing the degree of consistency between direct and indirect evidence
One primary assumption in our research was the adoption of consistency model, in which the consistency between direct and indirect evidence was validated by the node splitting method. Results of direct, indirect and network comparisons of these interventions were displayed in node splitting forest plots as shown in Fig. 7 , in which a P-value of less than 0.05 suggested significant inconsistency and resulted in violation of model. According to Fig. 7 , there was no significant inconsistency detected as all the P-value was larger than 0.05. Despite synthesis of information from disparate studies across several decades in different countries, the corresponding P-value confirmed the internal consistency of model and thereby validating the corresponding model assumptions.
Ranking of interventions
This NMA also provided us with a comprehensive ranking of various interventions by comparing their corresponding SUCRA values (Fig. 8) . A larger SUCRA indicated advantages over other treatments and a higher ranking accordingly. As illustrated in Table 3 , TER appeared to be the most preferable one with respect to new non-vertebral fractures (SUCRA = 0.780) and wrist fractures (SUCRA = 0.703), while DEN (SUCRA = 0.759) and ZOL (SUCRA = 0.754) were ranked the highest two with respect to hip fractures. As for adverse events, RAL was considered to be the most desirable with a SUCRA value of 0.874. The most three favorable interventions with respect to each endpoint were listed as the followings: TER, COL and ETI with respect to non-vertebral fractures; DEN, ZOL and ALE with respect to hip fractures; TER, EST+PRO and COL with respect to wrist fractures; RAL, ALE and DEN with respect to adverse events.
Discussion
In this systematic review and NMA, we compared 11 commonly-used agents for preventing new non-vertebral fractures, hip fractures, wrist fractures and adverse events in [50] because of government regulation, cost constrains and ethical issues. However, indirect comparisons derived from this NMA offers a solution to the lack of evidence.
The majority of the currently available NMAs have been conducted to estimate the treatment effect of multiple agents in the prevention of non-vertebral fractures [51, 52] . However, only bisphosphonates and PTH were involved in the majority of studies. To our knowledge, our analysis is the first one which included four key outcomes of new nonvertebral fractures and 11 agents including bisphosphonates (ALE, COL, ETI, RIS and ZOL), PTH (TER), biologics (DEN), selective EST receptor modulators (RAL, EST+PRO) and strontium ranelate (STR) versus PCB. Our NMA not only assessed the relative efficacy of these agents but also evaluated their relative safety by pooling evidence with respect to adverse events resulted from the use of these agents.
As suggested by our NMA, TER is probably the most preferable one with respect to preventing non-vertebral fractures and wrist fractures whereas DEN and ZOL appeared to have relatively strong performance with respect to hip fracture prevention. On the other hand, RAL outperformed others with respect to the endpoint of adverse events. Therefore, our NMA suggests that ALE, COL, DEN and TER are potentially the most effective osteoporotic treatments. However, direct comparisons for each intervention with PCB suggested that only ALE, COL, DEN and TER demonstrated statistically significant reductions in the risk of new vertebral fractures. Patients treated by ZOL, DEN and ALE also exhibited significantly difference in the risk of hip fractures compared to those received PCB. However, some results with respect to the endpoint of wrist fractures and hip fractures contained in the NMA appeared to be insignificant since only a small number of trials were involved in these two endpoints. In fact, our findings derived from NMA were consistent with those obtained from previous MA. For instance, Frediani et al. compared the relative efficacy COL for preventing new non-fractures in patients with osteoporosis and concluded that patients treated by COL were associated with a significant reduction in the risk of new non-vertebral fractures compared to those received PCB [53] . Another NMA concluded that bazedoxifene was relatively effective for preventing non-vertebral fractures [52] .
Several limitations contained in this study should be concerned and addressed in the future. Firstly, there was substantial variation in the corresponding endpoints that were assessed by individual studies and therefore the number of comparisons with respect to each endpoint may be affected. Secondly, we did not attempt to search for unpublished studies and potential publication bias may either underestimate or overestimate the summary statistics.
Conclusion
Teriparatide appears to be the most efficacious drug for preventing new non-vertebral fractures, etidronate and denosumab are desirable for balancing safety and efficacy well. Researches with respect to the relative safety and efficacy of osteoporotic therapies still have room for improvement. One major finding from our NMA indicates the lack of clinical trials that are able to compare the relative efficacy among DEN, ZOL and STR with respect to the outcome of wrist fractures or hip fractures. Therefore, more resources should be allocated to this area in order to overcome this issue. Apart from the relative efficacy and safety of osteoporotic therapies, several factors such as long-term side effects, affordability of therapies and compliance of patients to the corresponding therapy should be taken into account. Nevertheless, discovering the unknown characteristics of osteoporotic therapies is an iterative process and we expect our study to be an intuitive approach to discover these unknown parameters.
